Index of reports
> Disability (46)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine disability. The selected reports were submitted to the FDA during the sample period of about a year.
Reports 1 - 30 of 46 Next >>
Possible Vincristine side effects in 43 year old female
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-27
Patient: 43 year old female
Reactions: Off Label Use, Blindness
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Ifosfamide
Etoposide
Doxorubicin Hydrochloride
Vincristine
Possible Vincristine side effects in female
Reported by a physician from Canada on 2012-08-13
Patient: female
Reactions: Oral Herpes
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Prednisolone
Dosage: dose of last drug taken:100mg, date of recent dose taken prior to onset of ae:17/jun/2012
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-10
Vincristine
Dosage: route:intravenous push, dose of last drug taken:2mg, date of last dose taken prior to onset of ae:13
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-10
Doxorubicin Hydrochloride
Dosage: dose of last drug taken:91mg, date of last dose taken prior to onset of ae:13/jun/2012
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-10
Mabthera
Dosage: volume of last drug taken:343.5ml, dose concentration of last drug taken:1.99mg/ml, date of last do
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-10
Cyclophosphamide
Dosage: dose of last drug taken:1370mg, date of last dose taken prior to onset of ae:13/jun/2012
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-10
Other drugs received by patient: Colace; Polyethylene Glycol; Tramadol Hydrochloride and Acetaminophen; Senokot; Valacyclovir Hydrochloride; Codeine; Benzydamine; Naproxen; Morphine; Preparation H Cream; Lidocaine; Valacyclovir Hydrochloride; Ranitidine; YAZ; Morphine; Pantoprazole; Acetaminophen; Diphenhydramine Hydrochloride; Suppository (Unk Ingredients)
Possible Vincristine side effects in female
Reported by a physician from United Kingdom on 2012-07-27
Patient: female
Reactions: Myelopathy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Mabthera
Indication: Burkitt's Lymphoma
Doxorubicin Hydrochloride
Indication: Burkitt's Lymphoma
Vincristine
Indication: Burkitt's Lymphoma
Prednisone
Indication: Burkitt's Lymphoma
Cyclophosphamide
Indication: Burkitt's Lymphoma
Possible Vincristine side effects in female
Reported by a physician from United Kingdom on 2012-07-27
Patient: female
Reactions: Abasia, Myelopathy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Mabthera
Dosage: unk
Indication: Burkitt's Lymphoma
Vincristine
Dosage: unk
Indication: Product Used FOR Unknown Indication
Doxorubicin HCL
Dosage: unk
Prednisone TAB
Dosage: unk
Indication: Product Used FOR Unknown Indication
Cyclophosphamide
Dosage: unk
Possible Vincristine side effects in female
Reported by a physician from United Kingdom on 2012-07-23
Patient: female
Reactions: Abasia, Myelopathy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Prednisone
Doxorubicin Hydrochloride
Vincristine
Mabthera
Indication: Burkitt's Lymphoma
Cyclophosphamide
Possible Vincristine side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-07-17
Patient: female
Reactions: Palmar-Plantar Erythrodysaesthesia Syndrome, Paraesthesia
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Doxorubicin HCL
Start date: 2012-05-24
Cyclophosphamide
Start date: 2012-05-10
Vincristine
Start date: 2012-05-10
Cyclophosphamide
Start date: 2012-05-24
End date: 2012-05-24
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-05-10
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-05-24
Doxorubicin HCL
Start date: 2012-05-10
Vincristine
Start date: 2012-05-24
End date: 2012-05-24
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-05-24
Other drugs received by patient: Rituximab; Prednisone; Prednisone; Prednisone; Rituximab; Rituximab
Possible Vincristine side effects in female
Reported by a physician from United Kingdom on 2012-07-16
Patient: female
Reactions: Abasia, Myelopathy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: Product Used FOR Unknown Indication
Vincristine
Indication: Product Used FOR Unknown Indication
Mabthera
Indication: Burkitt's Lymphoma
Prednisone
Indication: Product Used FOR Unknown Indication
Cyclophosphamide
Indication: Product Used FOR Unknown Indication
Possible Vincristine side effects in 67 year old female
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-05
Patient: 67 year old female
Reactions: Cataract, Neuropathy Peripheral, Neutropenia
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Methotrexate
Dosage: 3500 mg/m2
Indication: Lymphoma
Rituximab (Rituximab) (Rituximab)
Dosage: 375 mg/m2
Indication: Lymphoma
Vincristine
Dosage: 1.4 mg/m2
Indication: Lymphoma
Procarbazine Hydrochloride
Dosage: 100 mg/m2, 1 in 1 d
Indication: Lymphoma
Possible Vincristine side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-07-03
Patient: female
Reactions: Palmar-Plantar Erythrodysaesthesia Syndrome
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Cyclophosphamide
Start date: 2012-05-10
Cyclophosphamide
Start date: 2012-05-24
Doxorubicin HCL
Start date: 2012-05-24
Vincristine
Start date: 2012-05-10
Vincristine
Start date: 2012-05-24
Rituxan
Start date: 2012-05-24
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Start date: 2012-05-10
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Rituxan
Start date: 2012-05-10
Prednisone
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Rituxan
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Prednisone
Start date: 2012-05-10
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Prednisone
Start date: 2012-05-24
Possible Vincristine side effects in 62 year old female
Reported by a health professional (non-physician/pharmacist) from Switzerland on 2012-06-30
Patient: 62 year old female
Reactions: Off Label Use, JC Virus Infection, Progressive Multifocal Leukoencephalopathy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Prednisone TAB
Dosage: 8 cycles
Indication: Hodgkin's Disease Recurrent
Etoposide
Indication: Hodgkin's Disease Recurrent
Procarbazine Hydrochloride
Dosage: 8 cycles
Indication: Hodgkin's Disease Recurrent
Doxorubicin HCL
Dosage: 8 cycles
Indication: Hodgkin's Disease Recurrent
Vincristine
Dosage: 8 cycles
Indication: Hodgkin's Disease Recurrent
Cyclophosphamide
Dosage: 8 cycles
Indication: Hodgkin's Disease Recurrent
Bleomycin Sulfate
Dosage: 8 cycles
Indication: Hodgkin's Disease Recurrent
Possible Vincristine side effects in 21 year old male
Reported by a health professional (non-physician/pharmacist) from France on 2012-05-30
Patient: 21 year old male, weighing 82.6 kg (181.7 pounds)
Reactions: Toxic Optic Neuropathy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Dexamethasone
Dosage: unk
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-10-20
End date: 2011-11-27
Valacyclovir Hydrochloride
Dosage: 1 g, 1x/day
Administration route: Oral
Start date: 2011-10-13
End date: 2011-12-07
Cerubidine
Dosage: 60 mg, cyclic
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-10-20
End date: 2011-11-10
Vfend
Dosage: unk
Start date: 2011-10-17
End date: 2011-12-07
Phenoxymethyl Penicillin
Dosage: 3 millioniu, 1x/day
Administration route: Oral
Start date: 2011-11-18
End date: 2011-12-07
Vincristine
Dosage: 2 mg, cyclic
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-10-20
End date: 2011-11-10
Nexium
Dosage: unk
Administration route: Oral
Start date: 2011-10-17
End date: 2011-11-11
Nexium
Dosage: unk
Administration route: Oral
Start date: 2011-11-15
End date: 2011-12-07
Kidrolase
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-10-24
End date: 2011-11-16
Other drugs received by patient: Methotrexate; Cyclophosphamide; Cytarabine
Possible Vincristine side effects in 35 year old male
Reported by a physician from Israel on 2012-05-29
Patient: 35 year old male
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 25 mg/m2, m2for 2 cycles of standard beacopp
Indication: Hodgkin's Disease
Etoposide
Dosage: 300 mg/m2, for 2 cycles of standard beacopp
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650 mg/m2for 2 cycles of standard beacopp
Indication: Hodgkin's Disease
Etoposide
Dosage: 600 mg/m2, for 4 cycles of escalated beacopp
Vincristine
Dosage: 1.4 mg/m2, for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Procarbazine
Dosage: 700 mg/m2, for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 1250 mg/m2 for 4 cycles of escalated beacopp
Bleomycin
Dosage: 10 mg/m2, for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Prednisone TAB
Dosage: 280 mg/m2,for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 35 mg/m2, for 4 cycles of escalated beacopp
Possible Vincristine side effects in 46 year old female
Reported by a physician from Israel on 2012-05-29
Patient: 46 year old female
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Etoposide
Dosage: 300 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Prednisone TAB
Dosage: 280 mg/m2, for 6 cycles
Bleomycin Sulfate
Dosage: 10 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Procarbazine
Dosage: 700 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Possible Vincristine side effects in female
Reported by a physician from France on 2012-05-25
Patient: female, weighing 45.0 kg (99.0 pounds)
Reactions: Malnutrition, Febrile Neutropenia, Febrile Bone Marrow Aplasia
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Dactinomycin
Dosage: last dose prior to sae : 29/mar/2012
Indication: Neoplasm Malignant
Start date: 2012-01-19
Vincristine
Dosage: last dose prior to sae 28/mar/2012
Indication: Neoplasm Malignant
Start date: 2012-01-19
Doxorubicin HCL
Dosage: last dose prior to sae 29/mar/2012
Indication: Neoplasm Malignant
Start date: 2012-01-19
Avastin
Dosage: last dose prior to sae: 22/mar/2012
Indication: Neoplasm Malignant
Start date: 2012-01-19
Ifosfamide
Dosage: last dose prior to sae 29/mar/2012
Indication: Neoplasm Malignant
Start date: 2012-01-19
Possible Vincristine side effects in male
Reported by a physician from France on 2012-05-25
Patient: male
Reactions: Toxic Optic Neuropathy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Vincristine
Dosage: 2mg cyclic
Indication: T-Cell Type Acute Leukaemia
Start date: 2011-10-20
End date: 2011-11-10
Phenoxymethyl Penicillin
Dosage: 3iu6 per day
Administration route: Oral
Indication: Product Used FOR Unknown Indication
Start date: 2011-11-18
End date: 2011-12-07
Nexium
Administration route: Oral
Indication: Product Used FOR Unknown Indication
Start date: 2011-10-17
End date: 2011-12-07
Vfend
Indication: Product Used FOR Unknown Indication
Start date: 2011-10-17
End date: 2011-12-07
Dexamethasone
Administration route: Oral
Indication: Product Used FOR Unknown Indication
Start date: 2011-10-20
End date: 2011-10-27
Valacyclovir Hydrochloride
Dosage: 1g per day
Administration route: Oral
Indication: Product Used FOR Unknown Indication
Start date: 2011-10-13
End date: 2011-12-07
Kidrolase
Dosage: 10iu3 cyclic
Indication: T-Cell Type Acute Leukaemia
Start date: 2011-10-24
End date: 2011-11-16
Cerubidine
Dosage: 60mg cyclic
Indication: T-Cell Type Acute Leukaemia
Start date: 2011-10-20
End date: 2011-11-10
Other drugs received by patient: Methotrexate; Cyclophosphamide; Cytarabine
Possible Vincristine side effects in 45 year old female
Reported by a physician from Israel on 2012-05-25
Patient: 45 year old female
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 25 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Etoposide
Dosage: 300 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Bleomycin
Dosage: 10 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 700 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Prednisone TAB
Dosage: 280 mg/m2, for 6 cycles
Indication: Hodgkin's Disease
Possible Vincristine side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-05-24
Patient: female
Reactions: Paraesthesia
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Doxorubicin HCL
Start date: 2010-05-20
End date: 2010-08-12
Vincristine
Start date: 2010-09-02
End date: 2010-10-14
Cyclophosphamide
Start date: 2010-05-20
End date: 2010-08-12
Cyclophosphamide
Start date: 2010-09-02
End date: 2010-10-14
Doxorubicin HCL
Start date: 2010-09-02
End date: 2010-10-14
Vincristine
Start date: 2010-05-20
End date: 2010-08-12
Other drugs received by patient: Prednisone TAB; Prednisone TAB
Possible Vincristine side effects in 21 year old male
Reported by a health professional (non-physician/pharmacist) from France on 2012-05-24
Patient: 21 year old male, weighing 82.6 kg (181.7 pounds)
Reactions: Toxic Optic Neuropathy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Vfend
Dosage: unk
Start date: 2011-10-17
End date: 2011-12-07
Nexium
Dosage: unk
Administration route: Oral
Start date: 2011-11-15
End date: 2011-12-07
Valacyclovir Hydrochloride
Dosage: 1 g, 1x/day
Administration route: Oral
Start date: 2011-10-13
End date: 2011-12-07
Dexamethasone
Dosage: unk
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-10-20
End date: 2011-11-27
Cerubidine
Dosage: 60 mg, cyclic
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-10-20
End date: 2011-11-10
Phenoxymethyl Penicillin
Dosage: 3 millioniu, 1x/day
Administration route: Oral
Start date: 2011-11-18
End date: 2011-12-07
Vincristine
Dosage: 2 mg, cyclic
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-10-20
End date: 2011-11-10
Nexium
Dosage: unk
Administration route: Oral
Start date: 2011-10-17
End date: 2011-11-11
Kidrolase
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-10-24
End date: 2011-11-16
Other drugs received by patient: Cyclophosphamide; Cytarabine; Methotrexate
Possible Vincristine side effects in 46 year old female
Reported by a health professional (non-physician/pharmacist) from Israel on 2012-05-23
Patient: 46 year old female
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 10 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Etoposide
Dosage: 300 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 700 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Prednisone
Dosage: 280 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Cytoxan
Dosage: 650 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Possible Vincristine side effects in 46 year old female
Reported by a health professional (non-physician/pharmacist) from Israel on 2012-05-23
Patient: 46 year old female
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 10 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Cytoxan
Dosage: 650 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 700 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Prednisone
Dosage: 280 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Etoposide
Dosage: 300 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Possible Vincristine side effects in male
Reported by a physician from France on 2012-05-23
Patient: male
Reactions: Toxic Optic Neuropathy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Vincristine
Dosage: 2 mg per course
Start date: 2011-10-27
Cerubidine
Dosage: 60 mg per course
Start date: 2011-10-20
Kidrolase
Start date: 2011-10-24
Vfend
Start date: 2011-10-17
End date: 2011-11-27
Valacyclovir Hydrochloride
Administration route: Oral
Start date: 2011-10-13
End date: 2011-12-07
Vincristine
Dosage: 2 mg per course
Start date: 2011-11-10
Cerubidine
Dosage: 60 mg per course
Start date: 2011-11-10
Vfend
Start date: 2011-11-28
End date: 2011-12-05
Dexamethasone
Dosage: daily
Administration route: Oral
Start date: 2011-10-20
End date: 2011-11-27
Phenoxymethyl Penicillin
Dosage: 3 000 000 iu
Administration route: Oral
Start date: 2011-11-18
End date: 2011-12-07
Kidrolase
Start date: 2011-10-27
Kidrolase
Start date: 2011-11-16
Cerubidine
Dosage: 60 mg per course
Start date: 2011-11-03
Nexium
Dosage: daily
Administration route: Oral
Start date: 2011-10-17
End date: 2011-11-11
Vincristine
Dosage: 2 mg per course
Start date: 2011-11-03
Kidrolase
Start date: 2011-11-10
Kidrolase
Start date: 2011-11-13
Kidrolase
Start date: 2011-11-06
Nexium
Administration route: Oral
Start date: 2011-11-15
End date: 2011-12-07
Vfend
Start date: 2011-12-06
End date: 2011-12-07
Vincristine
Dosage: 2 mg per course
Start date: 2011-10-20
Kidrolase
Start date: 2011-10-30
Kidrolase
Start date: 2011-11-03
Cerubidine
Dosage: 60 mg per course
Start date: 2011-10-27
Possible Vincristine side effects in 27 year old male
Reported by a physician from Israel on 2012-05-23
Patient: 27 year old male
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Etoposide
Dosage: 600 mg/m2,for 2 cycles of escalated beacopp
Vincristine
Dosage: 1.4 mg/m2, for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 1250 mg/m2, for 2 cycles of escalated beacopp
Prednisone TAB
Dosage: 280 mg/m2, for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Etoposide
Dosage: 300 mg/m2, for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Bleomycin Sulfate
Dosage: 10 mg/m2, for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650 mg/m2,for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2, for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 35 mg/m2, for 2 cycles of escalated beacopp
Procarbazine Hydrochloride
Dosage: 700 mg/m2, for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Possible Vincristine side effects in 30 year old male
Reported by a physician from Israel on 2012-05-21
Patient: 30 year old male
Reactions: Pulmonary Toxicity, Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Prednisone
Dosage: 280 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Bleomycin
Dosage: 10 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Cytoxan
Dosage: 650 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Etoposide
Dosage: 300 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 700 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Possible Vincristine side effects in 45 year old female
Reported by a physician from Israel on 2012-05-21
Patient: 45 year old female
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Etoposide
Dosage: 300 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Cytoxan
Dosage: 650 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Bleomycin
Dosage: 10 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Prednisone
Dosage: 280 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 700 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Possible Vincristine side effects in 46 year old female
Reported by a physician from Israel on 2012-05-18
Patient: 46 year old female
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 25 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Bleomycin Sulfate
Dosage: 10 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 700 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Etoposide
Dosage: 300 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Prednisone
Dosage: 280 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Possible Vincristine side effects in 35 year old male
Reported by a physician from Israel on 2012-05-18
Patient: 35 year old male
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Etoposide
Dosage: 600 mg/m2600 mg/m2 for 4 cycles of escalated beacopp
Vincristine
Dosage: 1.4 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2for 2 cycles of standard beacopp
Indication: Hodgkin's Disease
Bleomycin Sulfate
Dosage: 10 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Prednisone
Dosage: 280 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 35 mg/m2 for 4 cycles of escalated beacopp
Etoposide
Dosage: 300 mg/m2 for 2 cycles of standard beacopp
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 1250 mg/m2 for 4 cycles of escalated beacopp
Procarbazine Hydrochloride
Dosage: 700 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650 mg/m2for 2 cycles of standard beacopp
Indication: Hodgkin's Disease
Possible Vincristine side effects in 27 year old male
Reported by a physician from Israel on 2012-05-18
Patient: 27 year old male
Reactions: Dyspnoea
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 35 mg/m2 for 2 cycles of escalated beacopp
Bleomycin Sulfate
Dosage: 10 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Etoposide
Dosage: 600 mg/m2 for 2 cycles of escalated beacopp
Doxorubicin HCL
Dosage: 25 mg/m2 for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Prednisone
Dosage: 280 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Etoposide
Dosage: 300 mg/m2 for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 1250 mg/m2 for 2 cycles of escalated beacopp
Procarbazine Hydrochloride
Dosage: 700 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650 mg/m2 for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Possible Vincristine side effects in 27 year old male
Reported by a health professional (non-physician/pharmacist) from Israel on 2012-05-08
Patient: 27 year old male
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Etoposide
Dosage: 300 mg/m2 for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Etoposide
Dosage: 600 mg/m2 for 2 cycles of escalated beacopp
Cyclophosphamide
Dosage: 650 mg/m2 for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 1250 mg/m2 for 2 cycles of escalated beacopp
Procarbazine Hydrochloride
Dosage: 700 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Bleomycin Sulfate
Dosage: 10 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2 for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 35 mg/m2 for 2 cycles of escalated beacopp
Prednisone TAB
Dosage: 280 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Possible Vincristine side effects in 27 year old male
Reported by a health professional (non-physician/pharmacist) from Israel on 2012-05-08
Patient: 27 year old male
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Vincristine
Dosage: 1.4 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2 for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Etoposide
Dosage: 300 mg/m2 for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 35 mg/m2 for 2 cycles of escalated beacopp
Bleomycin Sulfate
Dosage: 10 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 700 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Prednisone TAB
Dosage: 280 mg/m2 for all 6 cycles of beacopp
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 1250 mg/m2 for 2 cycles of escalated beacopp
Etoposide
Dosage: 600 mg/m2 for 2 cycles of escalated beacopp
Cyclophosphamide
Dosage: 650 mg/m2 for 4 cycles of standard beacopp
Indication: Hodgkin's Disease
Possible Vincristine side effects in 45 year old female
Reported by a health professional (non-physician/pharmacist) from Israel on 2012-05-07
Patient: 45 year old female
Reactions: Respiratory Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Etoposide
Dosage: 300 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Prednisone
Dosage: 280 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Bleomycin Sulfate
Dosage: 10 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 700 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2 for 6 cycles
Indication: Hodgkin's Disease
Page 1 Next >>
|